Similar articles for PMID: 22761478

Year	Number of Results
2004	1
2006	1
2007	4
2008	7
2009	10
2010	6
2011	16
2012	21
2013	33
2014	18
2015	7
2016	8
2017	11
2018	9
2019	2
2020	1
2021	2
2022	5
2023	1
2024	0

1

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.

Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Colmers IN, et al. CMAJ. 2012 Sep 4;184(12):E675-83. doi: 10.1503/cmaj.112102. Epub 2012 Jul 3. CMAJ. 2012. PMID: 22761478 Free PMC article.

2

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.

Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, Keskimäki I, Badrick E, Renehan AG, Buchan IE, Bowker SL, Minhas-Sandhu JK, Zafari Z, Marra C, Johnson JA, Stricker BH, Uitterlinden AG, Hofman A, Ruiter R, de Keyser CE, MacDonald TM, Wild SH, McKeigue PM, Colhoun HM; Scottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research Consortium. Levin D, et al. Diabetologia. 2015 Mar;58(3):493-504. doi: 10.1007/s00125-014-3456-9. Epub 2014 Dec 7. Diabetologia. 2015. PMID: 25481707

3

Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.

Turner RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK. Turner RM, et al. Br J Clin Pharmacol. 2014 Aug;78(2):258-73. doi: 10.1111/bcp.12306. Br J Clin Pharmacol. 2014. PMID: 24325197 Free PMC article.

4

Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.

Han E, Jang SY, Kim G, Lee YH, Choe EY, Nam CM, Kang ES. Han E, et al. Medicine (Baltimore). 2016 Feb;95(6):e2786. doi: 10.1097/MD.0000000000002786. Medicine (Baltimore). 2016. PMID: 26871835 Free PMC article.

5

Pioglitazone use and risk of bladder cancer: population based cohort study.

Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Tuccori M, et al. BMJ. 2016 Mar 30;352:i1541. doi: 10.1136/bmj.i1541. BMJ. 2016. PMID: 27029385 Free PMC article.

6

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD. Mamtani R, et al. J Natl Cancer Inst. 2012 Sep 19;104(18):1411-21. doi: 10.1093/jnci/djs328. Epub 2012 Aug 9. J Natl Cancer Inst. 2012. PMID: 22878886 Free PMC article.

7

Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.

Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS. Hsiao FY, et al. Drug Saf. 2013 Aug;36(8):643-9. doi: 10.1007/s40264-013-0080-4. Drug Saf. 2013. PMID: 23797604

8

Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials.

Monami M, Dicembrini I, Mannucci E. Monami M, et al. Acta Diabetol. 2014 Feb;51(1):91-101. doi: 10.1007/s00592-013-0504-8. Epub 2013 Jul 14. Acta Diabetol. 2014. PMID: 23851465

9

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.

Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. Zhu Z, et al. Diabetes Res Clin Pract. 2012 Oct;98(1):159-63. doi: 10.1016/j.diabres.2012.05.006. Epub 2012 Jun 16. Diabetes Res Clin Pract. 2012. PMID: 22705039

10

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

Loke YK, Singh S, Furberg CD. Loke YK, et al. CMAJ. 2009 Jan 6;180(1):32-9. doi: 10.1503/cmaj.080486. Epub 2008 Dec 10. CMAJ. 2009. PMID: 19073651 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

140 results

Results by year